Aclaris Therapeutics Inc. plans to sell its common shares in an underwritten public offering.

The company also plans to grant the underwriters an option to buy up to an additional 15% of the common shares in the offering.

Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering.

The Wayne, Pa.-based biopharmaceutical company develops therapies for medical and aesthetic dermatology and immunology in the U.S.